New Healthcare market report from Business Monitor International: "Canada Pharmaceuticals & Healthcare Report Q2 2014"

Boston, MA -- (SBWire) -- 04/10/2014 --On the back of more promising a macroeconomic outlook in 2014, we believe the Canadian pharmaceutical and healthcare market will be more attractive to pharmaceutical companies. Although drugmakers will continue to face generic competition and drug pricing pressure in the country, improving healthcare coverage and broader drug reimbursement lists will increase patients' access to medicines and provide revenue-generating opportunities for drugmakers.

Headline Expenditure Projections

- Pharmaceuticals: CAD25.6bn (US$24.7bn) in 2013 to CAD25.9bn (US$24.6bn) in 2014; +0.9% in local currency terms and -0.1% in US dollar terms. Forecast changed from Q114 due to changes to macroeconomic data.
- Healthcare: CAD206.5bn (US$198.5bn) in 2013 to CAD214.6bn (US$204.4bn) in 2014; +4.0% in local currency terms and +3.0% in US dollar terms. Forecast up from Q114 due to changes to macroeconomic data.

View Full Report Details and Table of Contents

Risk/Reward Rating

Canada scores 68.7 in BMI's Pharmaceutical and Healthcare Risk/Reward Ratings (RRR) matrix, making it the second-most attractive pharmaceutical market in America. We have re-weighted the RRR components to improve the tool, and adjusted scores for all markets in our Pharmaceuticals and Healthcare reports.

Key Trends And Developments

- In January 2014, Valeant Pharmaceutical's CEO Michael Pearson announced the company's new strategic initiatives. Within three years, Pearson aims for Valeant to become one of the five most valuable companies in the world in terms of market capitalisation..
- In December 2013, the province of New Brunswick in Canada launched a new prescription drug coverage plan, which is designed to cover medicine costs for people who do not have insurance through their employers.
- In November 2013, the Supreme Court of Canada announced that Ontario's 2010 regulations, created to prevent pharmacy chains from selling their own generic versions of prescription medications, are a legitimate aspect of its efforts to control prescription drug costs.

BMI Economic View: We expect an improvement in Canadian real GDP growth in 2014 and 2015, with expansion of 2.1% and 2.3% in those years, respectively (up from 1.7% in both 2012 and 2013). However, our forecasts are below consensus, and we expect domestic demand to come under pressure as overleveraged households take a breather, the housing market cools, and commodity prices fail to recover.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Sweden Pharmaceuticals & Healthcare Report Q2 2014
- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Bangladesh Pharmaceuticals & Healthcare Report Q2 2014
- Mexico Pharmaceuticals & Healthcare Report Q2 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q2 2014
- Thailand Pharmaceuticals & Healthcare Report Q2 2014
- Kazakhstan Pharmaceuticals & Healthcare Report Q2 2014
- Lebanon Pharmaceuticals & Healthcare Report Q2 2014
- Japan Pharmaceuticals & Healthcare Report Q2 2014